A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1 drugs currently available for weight loss are administered as once-weekly injections. Verdiva Bio also aims to bring to patients once-a-week dosing, but in a more convenient pill. That would ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

The results also showed that the patients taking the GLP-1 RA drugs have a 12 per cent lower risk of hospital re-admission ...

Taking the ‘GLP-1 receptor agonist’ class of anti-obesity drugs is related with lower rates of post-surgery complications in ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

Patients taking the anti-obesity drugs had about 12% lower risk of hospital re-admission within a month of surgery, compared ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

GLP-1 RA drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low levels of which can lead to diabetes. Taking the 'GLP-1 receptor agonist ...